After more than 100 years of scientific effort, the World Health Organization has recommended the world’s first malaria vaccine for broad use across sub-Saharan Africa and other high-transmission regions. The vaccine — called RTS,S — marks one of the most significant achievements in the history of medicine, with the WHO saying it could save tens of thousands of young children’s lives every year.
At a glance
- RTS,S vaccine: Developed by pharmaceutical giant GSK, the shot targets Plasmodium falciparum, the deadliest and most common malaria parasite in Africa, and was shown to prevent around four in 10 malaria cases in trials.
- Malaria deaths in children: More than 260,000 children died from malaria in Africa in 2019 C.E. alone — making the disease one of the leading killers of young children on the continent for generations.
- Pilot immunization programs: Data from more than 2.3 million doses administered in Ghana, Kenya, and Malawi confirmed the vaccine is safe and effective in real-world conditions, giving the WHO confidence to recommend a full rollout.
A century in the making
Malaria is caused by a parasite — not a virus or bacterium — and that distinction matters enormously. The Plasmodium parasite has evolved over millions of years to evade the human immune system. It cycles between mosquitoes and humans, shifting between forms as it infects liver cells and red blood cells. That biological complexity is why vaccine development took so long, and why the 40% efficacy rate, while modest by some standards, is considered a remarkable scientific feat.
“We’ve been looking for a malaria vaccine for over 100 years now,” said Dr. Pedro Alonso, director of the WHO Global Malaria Programme. “It will save lives and prevent disease in African children.”
Dr. Tedros Adhanom Ghebreyesus, director-general of the WHO, called the recommendation “a historic moment.” He added that the vaccine “could save tens of thousands of young lives each year.”
From pilot to continent-wide rollout
The path from proven efficacy to WHO recommendation ran through three African countries. Ghana, Kenya, and Malawi ran large-scale pilot immunization programs to test whether mass vaccination was logistically feasible and whether the vaccine held up outside controlled trial conditions. It did.
Dr. Kwame Amponsa-Achiano led the pilot in Ghana — a country where he grew up catching malaria nearly every week as a child. That experience drove him to medicine. “It was distressing,” he said. “Almost every week you were out of school. Malaria has taken a toll on us for a long time.” Now, he says, large-scale vaccination should reduce the malaria toll “to the barest minimum.”
The vaccine requires four doses: three given a month apart at five, six, and seven months of age, followed by a booster at around 18 months. That schedule raised early doubts about real-world effectiveness. The pilot results answered those doubts convincingly, drawing on data from more than 2.3 million doses across three countries.
What it means — and what it doesn’t replace
The WHO’s recommendation is not a signal to abandon other tools. Insecticide-treated bed nets, antimalarial drugs, and mosquito control programs remain essential. RTS,S is designed to work alongside them, layering protection to push closer to the goal of zero malaria deaths.
The vaccine also won’t be used outside of Africa, where different Plasmodium species — which RTS,S cannot protect against — are more prevalent. That limitation reflects an honest picture of where this tool fits in a broader global strategy.
Dr. Ashley Birkett of the Path malaria vaccine initiative described the rollout as a “historic event” that would “take away fear” from families. “Imagine your young child could be healthy one day and full of potential,” he said, “and then after the bite of an infected mosquito, while playing with friends or sleeping in a bed, they could be dead in a couple of weeks.”
The road still ahead
RTS,S is a beginning, not a finish line. The 40% efficacy rate, while genuinely historic, leaves room — and urgent need — for more potent next-generation vaccines. The WHO’s formal recommendation is expected to unlock funding from global health bodies and accelerate manufacturing and distribution planning. Gavi, the Vaccine Alliance, has signaled interest in financing the rollout for lower-income countries, which carry the heaviest burden of malaria deaths.
Supply will be a central challenge. GSK has committed to producing up to 15 million doses a year through 2028 C.E., but estimates suggest demand could far exceed that as more countries seek access. Equitable distribution — ensuring the vaccine reaches the most remote and underserved communities — will require sustained coordination between governments, donors, and health systems that are still recovering from the strain of the COVID-19 pandemic.
The science is also still moving. A second malaria vaccine, R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, showed efficacy rates above 70% in early trials, raising hopes that even more powerful tools are on the horizon. Both vaccines target the same stage of the parasite’s life cycle, but researchers believe combining approaches — vaccines, nets, drugs, and vector control — offers the best path toward a malaria-free future.
For now, the world has something it has never had before: a licensed, WHO-recommended vaccine against one of history’s most persistent killers. That alone is worth pausing to recognize.
Read more
For more on this story, see: BBC News
For more from Good News for Humankind, see:
- Ghana establishes a major marine protected area at Cape Three Points
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
